GcMAF Therapy for Autism

Worldwide over 2500 autistic children have been treated with GcMAF and this is what we have learned:

How GcMAF can help Autism

Autism is not limited to, but is the result of many viral and bacterial infections.  Over 85% of children tested have an elevated level of nagalase which indicates that the immune system is under stress from viral and bacterial infections.  Therefore it can be proposed that GcMAF could be combined with other therapies to treat the symptoms of autism.  An average time span for GcMAF therapy is 20 weeks for autism

What is GcMAF

GcMAF is a sugar protein (Gc) that acts as a Macrophage Activating Factor (MAF) in the immune system.   It is part of the Active Vitamin D Molecule (1,25-dihydroxyvitamin D3), produced in the liver, is completely natural and the body expects it.  Over 57 research papers have been published that demonstrate GcMAF activates Macrophages in both in vivo and in vitro studies.

Nagalase - Collapsing the Immune System

In order to defeat the immune system and be able to grow and spread unchecked, viruses and bacteria secrete an enzyme called Nagalase which prevents the human body from producing its own GMAF.  At a biological level the human body is constantly under attack so there is an excepted 'normal' level at 0.65 nmol/mg.  Levels above 0.65 nmol/mg indicate the immune system may have been compromised and the macrophages are not activated.  85% of autistic children are found to have high levels of Nagalase.

Activating the Immune System

Macrophages function in both non-specific defence (innate immunity) as well as help initiate specific defence mechanisms (adaptive immunity) of vertebrate animals.  Their role is to phagocytise (engulf and then digest) cellular debris and pathogens, either as stationary or as mobile cells.  They also stimulate lymphocytes and other immune cells to respond to pathogens.  They are specialized phagocytic cells that attack foreign substances, infectious microbes and cancer cells through destruction and ingestion.

GcMAF Therapy for Autism

GcMAF is simply a protein replacement therapy, giving the body the protein it should be producing and expects.  Dr. Yamamoto’s three studies showed that incredibly small weekly doses (100 billionths of a gram—an amount that is invisible to the naked eye) of GcMAF had cured early metastatic breast, prostate, and colon cancers in 100% of (non anaemic) patients. In a fourth paper, he used the same treatment to cure 100% of non anaemic HIV-infected patients. More recently Dr Bradstreet & Dr Antonucci have performed GcMAF therapy on over 2000 autistic children with encouraging results.  Over 85% have responded favourably to GcMAF and 15% of these have lost the label of autism altogether

Side effects with GcMAF

Dr. Yamamoto states in many of his research papers that:

".... generated the most potent macrophage-activating factor (GcMAF) ever discovered, but it produces no side effect in humans."

But an awakened immune system will deal with these pathogens in no particular order and any side effects will be the result of an active immune system.  Be aware, and make note of any immune responses such as low grade fevers and bacterial flare ups. These can be seen as a positive sign that the immune system is functioning. If the symptoms become aggravated then reduce the dosage of GcMAF.

With autism, it is best to start at a low dose, these symptoms should never be more than a headache, low grade fever, or flu like symptoms.  The initial dose can be started as low as 0.01 - 0.05ml, with two injections per week.  The dose can be increased slowly, and should the patient start to regress, the dose should be lowered.  It is best to do this under the supervision of a doctor who is knowledgeable with GcMAF and its actions, but if this is not possible, there is a Facebook group called ‘GcMAF’ where many parents and patients share their knowledge and experiences. 

GcMAF – moving forward

Although over 4000 patients are now using GcMAF, the mechanism by which it helps autism is still not fully understood.  GcMAF is a complex and multi-faceted molecule, and much more than just a macrophage activating tool:

  • It turns cancer cells back to normal cells.
  • It activates the Vitamin D receptor pathways.
  • It improves bone density.
  • It works as an actin scavenger, cleaning the body of toxins. 

The Nagalase improvements in the autism trial indicate that the viral load of the autistic patients decreases, so it is speculated that a reduction in the viral load creates a reduction in endotoxins which may explain some of the improvements in autistic behaviours. 

They simply now have a clearer head, similar to no longer being intoxicated.  In addition, there are three common alleles of GcProtein, and it may be that some variants of these may cause the GcMAF not to work on 15% of the population.  This requires further study, as all humans need GcMAF, but some may need a different variation.

Useful References

Dr Bradstreet Blog  http://drbradstreet.org/category/autism/

Dr Bradstreet Paper on Autism & Nagalase Initial Observations of Elevated Alpha-N-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections

Dr Nicola Antonucci presentations and pages

GcMAF Facebook Page: https://www.facebook.com/groups/528429853856138/

GcMAF Book -  http://gcmaf.timsmithmd.com/

Dr Yamamoto Papers - http://www.gc-maf.de/en/the-yamamoto-papers.html

Disclaimer

Nothing stated here should be considered as medical advice for dealing with a given problem. You should consult your Doctor for individual guidance for specific health problems. The information contained here is for informational and educational purposes only.

GcMAF is a sugar protein (Gc) that acts as a Macrophage Activating Factor (MAF) in the immune system.  It is part of the Active Vitamin D Molecule (1,25-dihydroxyvitamin D3), produced in the liver, is completely natural and the body expects it. Over 57 research papers have been published that demonstrate GcMAF activates Macrophages in both in vivo and in vitro studies